Jonathan Max Gitlin is a Science Policy Analyst within the Policy and Program Analysis Branch (PPAB) of the Office of the Director at the National Human Genome Research Institute (NHGRI). At NHGRI he focuses on policy areas including gene patenting and intellectual property, newborn screening, and the regulation of genetic tests.
Dr Gitlin received his B.Sc. in pharmacology from King's College London, and his Ph.D. in pharmacology from Imperial College London, following which he conducted research in cardiovascular disease at The Scripps Research Institute and the University of Kentucky.
Additionally, Dr. Gitlin is a contributing writer for the online publication Ars Technica, and taught international science and technology policy at the University of Kentucky's Patterson School of Diplomacy and International Commerce.
Top of page
Last Reviewed: December 13, 2011